Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
11.29M | 7.77M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
851.00K | 3.03M | -112.09M | -92.31M | -50.51M | -28.83M | EBIT |
-82.59M | -118.38M | -112.09M | -92.31M | -50.51M | -28.83M | EBITDA |
-79.16M | -114.09M | -110.84M | -92.26M | -50.48M | -28.80M | Net Income Common Stockholders |
-135.25M | -116.66M | -116.88M | -92.29M | -52.17M | -31.09M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
25.03M | 24.95M | 120.23M | 178.66M | 77.07M | 11.25M | Total Assets |
26.32M | 154.46M | 225.69M | 240.90M | 98.18M | 14.56M | Total Debt |
0.00 | 9.81M | 760.00K | 956.00K | 1.31M | 358.00K | Net Debt |
-25.03M | -15.13M | -119.47M | -177.70M | -75.76M | -10.89M | Total Liabilities |
2.65M | 48.93M | 18.51M | 22.18M | 10.54M | 5.14M | Stockholders Equity |
23.66M | 105.53M | 207.18M | 218.72M | 87.65M | 9.42M |
Cash Flow | Free Cash Flow | ||||
-68.46M | -109.90M | -146.20M | -110.86M | -57.13M | -26.70M | Operating Cash Flow |
-67.53M | -102.00M | -98.05M | -75.56M | -48.57M | -26.68M | Investing Cash Flow |
-215.60K | -29.07M | -48.15M | -35.31M | -8.56M | -17.00K | Financing Cash Flow |
90.89M | 36.52M | 87.84M | 212.49M | 123.11M | 12.92M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $76.20M | ― | -138.69% | ― | 183.05% | -83.05% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
45 Neutral | $6.95M | ― | -30.36% | ― | ― | 86.52% | |
38 Underperform | $31.18M | ― | -596.70% | ― | ― | 9.74% | |
36 Underperform | $27.75M | ― | -132.62% | ― | -97.70% | -126.39% | |
32 Underperform | $72.80M | ― | -23.98% | ― | ― | -19.93% | |
31 Underperform | $5.02M | ― | -2639.52% | ― | ― | 19.58% |
Tonix Pharmaceuticals has appointed Gary Ainsworth as Vice President of Market Access, signaling potential strategic shifts in market positioning. The company also announced the expected timelines for topline data from its TNX-1300 Phase 2 study for cocaine intoxication and TNX-1500 Phase 1 study for kidney transplant rejection, marking significant steps in their product development pipeline.
Tonix Pharmaceuticals announced that the FDA has set a Prescription Drug User Fee Act goal date of August 15, 2025, for its decision on the marketing approval of TNX-102 SL, a product candidate aimed at managing fibromyalgia. This milestone could significantly impact Tonix’s market positioning and influence stakeholder expectations within the pharmaceutical industry.
Tonix Pharmaceuticals announced the FDA’s acceptance of its New Drug Application for TNX-102 SL, a non-opioid analgesic for fibromyalgia. This acceptance marks potential progress toward introducing the first new fibromyalgia drug in over 15 years, potentially reducing reliance on opioids, and signifies a significant milestone as Tonix prepares for potential market approval in 2025.
Tonix Pharmaceuticals is strategically strengthening its leadership team by appointing new executives as it prepares for significant progress with its TNX-102 SL product aimed at managing fibromyalgia. The company anticipates beginning a new study for acute stress reactions in early 2025 and awaits a potential FDA decision on its New Drug Application by August 2025. Investors are advised to consider forward-looking statements with caution due to inherent uncertainties.
Tonix Pharmaceuticals has unveiled promising data for its TNX-801 vaccine, showing it is less virulent in immune-compromised mice compared to 20th-century vaccinia vaccines. This breakthrough suggests TNX-801 could be an effective candidate in controlling mpox spread. Investors should note the company’s forward-looking statements about product development and potential growth, while being mindful of inherent market risks.
Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising results of its TNX-1700 candidate in cancer treatment. Collaborating with Columbia University scientists, the study demonstrated that TNX-1700 enhanced the effects of anti-PD-1 therapy, leading to tumor regression and prolonged survival in animal models. These findings highlight TNX-1700’s potential to revolutionize immunotherapy by targeting specific immune suppressor cells, offering hope for improved cancer treatments.
Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute to launch a Phase I clinical trial for its TNX-801 vaccine aimed at preventing mpox and smallpox. This collaboration will see Tonix sponsoring the trial while KEMRI leads its execution, marking a significant step in vaccine development and regulatory approval processes. Investors should note that this announcement includes forward-looking statements about the company’s future operations and market potential.